TTI-621 (SIRPαFc): A CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding

Clinical Cancer Research

Volumn 23, Issue 4, 2017, Pages 1068-1079

  Petrova, Penka S ^a   Viller, Natasja Nielsen ^a   Wong, Mark ^a   Pang, Xinli ^a   Lin, Gloria H Y ^a   Dodge, Karen ^a   Chai, Vien ^a   Chen, Hui ^a   Lee, Vivian ^a   House, Violetta ^a   Vigo, Noel T ^a   Jin, Debbie ^a   Mutukura, Tapfuma ^a   Charbonneau, Marilyse ^a   Truong, Tran ^a   Viau, Stephane ^a   Johnson, Lisa D ^a   Linderoth, Emma ^a   Sievers, Eric L ^a   Vareki, Saman Maleki ^b,c   Figueredo, Rene ^b,c   Pampillo, Macarena ^b   Koropatnick, James ^b,c   Trudel, Suzanne ^d   Mbong, Nathan ^d   Jin, Liqing ^d   Wang, Jean C Y ^d,e,f   Uger, Robert A ^a   more..

^a Trillium Therapeutics Inc   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G1; PROTEIN INHIBITOR; TTI 621; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; CD47 PROTEIN, HUMAN; DIFFERENTIATION ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN BINDING; SIRPA PROTEIN, HUMAN; TTI-621;

ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DRUG STRUCTURE; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOLOGY; NEOPLASM; PATHOLOGY; PROTEIN PROTEIN INTERACTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION; CD47 ANTIGEN; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN G; MICE; NEOPLASMS; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN INTERACTION MAPS; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85012939247     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1700     Document Type: Article

References (37)

1. Tsai RK, Discher DE. Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 2008;180:989-1003.
2. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science 2000;288:2051-4.
3. Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 2005;105:3577-82.
4. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-57.
5. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271-85.
6. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KDJr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009;138:286-99.
7. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010;142:699-713.
8. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 2011;71:1374-84.
9. Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012;26:2538-45.
10. Pang WW, Pluvinage JV, Price EA, Sridhar K, Arber DA, Greenberg PL, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A 2013;110:3011-6.
11. Nagahara M, Mimori K, Kataoka A, Ishii H, Tanaka F, Nakagawa T, et al. Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res 2010;16:4625-35.
12. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A 2012;109:6656-61.
13. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012;109:6662-7.
14. Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP, et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther 2013;21:1919-29.
15. Cioffi M, Trabulo S, Hidalgo M, Costello E, Greenhalf W, Erkan M, et al. Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms. Clin Cancer Res 2015;21:2325-37.
16. Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van HM, Otten MA, et al. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 2011;108:18342-7.
17. Steinert G, Scholch S, Niemietz T, Iwata N, Garcia SA, Behrens B, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 2014;74:1694-704.
18. Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 2011;118:4890-901.
19. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Pre-Clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE 2015;10:e0137345.
20. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999;29:2613-24.
21. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993;30:105-8.
22. Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI, et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 2007;8:1313-23.
23. Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013;341:88-91.
24. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010;31:212-9.
25. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 2009;113:3716-25.
26. Lin GHY, Chai V, Lee V, Dodge K, Truong T, Wong M, et al. SIRPαFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages [abstract]. In: Proceedings of the AACR 107th Annual Meeting; 2016 Apr 16-20, 2016; New Orleans, LA; Philadelphia (PA): AACR; 2016. Abstract nr 2345.
27. Theocharides AP, Jin L, Cheng PY, Prasolava TK, Malko AV, Ho JM, et al. Disruption of SIRPalpha signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 2012;209:1883-99.
28. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010;2:63ra94.
29. Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 2013;110:11103-8.
30. Mouro-Chanteloup I, Delaunay J, Gane P, Nicolas V, Johansen M, Brown EJ, et al. Evidence that the red cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47. Blood 2003;101:338-44.
31. Burger P, Hilarius-Stokman P, de KD, van den Berg TK, van BR. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 2012;119:5512-21.
32. Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, et al. SIRPα-antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells. Clin Cancer Res. 2016 Oct 15. [Epub ahead of print].
33. Subramanian S, Tsai R, Sen S, Dahl KN, Discher DE. Membrane mobility and clustering of Integrin Associated Protein (IAP, CD47) - major differences between mouse and man and implications for signaling. Blood Cells Mol Dis 2006;36:364-72.
34. Uger RA, Dodge K, Pang X, Petrova PS. Cancer immunotherapy targeting CD47: wild type SIRPαFc is the ideal CD47-blocking agent to minimize unwanted erythrocyte binding [abstract]. In: Proceedings of the AACR Annual Meeting; 2014 Apr 5-9; San Diego, CA; Philadelphia (PA): AACR; 2014. Abstract nr 5011.
35. Oostendorp M, Lammerts van Bueren JJ, Doshi P, Khan I, Ahmadi T, Parren PWHI, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 2015;55:1555-62.
36. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015;55:1545-54.
37. Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 2015;21:1209-15.